Geoffrey von Maltzahn is co-Founder, chief executive officer, and board director of Tessera Therapeutics, as well as a general partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental sustainability. He is a co-founder of Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Indigo Agriculture, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), Axcella Health (NASDAQ:AXLA), and others that have, in aggregate, achieved over $10 billion in public and private market capitalization.

Geoffrey currently serves as chief innovation officer and board director of Indigo, where he first served as chief executive officer to lead the development of the company’s technology platform and discovery of the company’s first commercial products. While he was CEO when he started his companies he is now a Board Director for Kaleido, Generate, Cobalt Biomedicine (now part of Sana Biotechnology). In Kaleido’s early stages Geoff led the company from inception to launching multiple clinical studies. Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109, the first microbiome therapeutic to report positive phase 3 data.

Geoffrey is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles.

Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.